Onco Wiki / Maladie

Mésothéliome pleural maligne (MPM)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-MESOTHELIOMA
TypeMaladie
Alias
Mésothéliome maligneMésothéliome NOSMésothéliome péritonéalЗлоякісна мезотеліома плеври
Étatreviewed 2026-05-04 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesAucune déclaration

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9050/3
icd_o_3_topography["C38.4", "C48.1", "C48.2"]
icd_10C45.0
who_classificationWHO Thoracic Tumours 5th ed (2021): Mesothelioma

Capacités

Notes

Malignant mesothelioma is predominantly a pleural cancer (MPM ~80% of cases); peritoneal mesothelioma (~20%) has different treatment (cytoreductive surgery + hyperthermic intraperitoneal chemotherapy [HIPEC] for peritoneal). This disease entity focuses on MPM. Historically extremely poor prognosis (mOS ~12 mo); CheckMate-743 (FDA 2020) with nivolumab+ipilimumab improved mOS to 18.1 mo — first new 1L approval in 15 years. BAP1 IHC loss is a diagnostic marker (not actionable therapeutically). PD-L1 expression is not validated as predictive for ICI benefit in MPM.

Utilisé par

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Protocole thérapeutique

Sources